Floatz logo

Ixabepilone

Bilateral Breast Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Bilateral Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Sargramostim
Academic and Community Cancer Research United
Phase 2CCC
Cyclophosphamide
Academic and Community Cancer Research United
Phase 2CCC
vx-970
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Ixabepilone is also rated in:

breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
metastatic neoplasmDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →